UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
![]() |
|||||||
|
Fusion Protein:NACC2-NTRK2 |
Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: NACC2-NTRK2 | FusionPDB ID: 57095 | FusionGDB2.0 ID: 57095 | Hgene | Tgene | Gene symbol | NACC2 | NTRK2 | Gene ID | 138151 | 4915 |
Gene name | NACC family member 2 | neurotrophic receptor tyrosine kinase 2 | |
Synonyms | BEND9|BTBD14|BTBD14A|BTBD31|NAC-2|RBB | EIEE58|GP145-TrkB|OBHD|TRKB|trk-B | |
Cytomap | 9q34.3 | 9q21.33 | |
Type of gene | protein-coding | protein-coding | |
Description | nucleus accumbens-associated protein 2BEN domain containing 9BTB (POZ) domain containing 14ABTB/POZ domain-containing protein 14ANACC family member 2, BEN and BTB (POZ) domain containingrepressor with BTB domain and BEN domaintranscription repressor | BDNF/NT-3 growth factors receptorBDNF-tropomyosine receptor kinase Bneurotrophic tyrosine kinase receptor type 2tropomyosin-related kinase Btyrosine kinase receptor B | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q96BF6 | Q16620 | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000371753, ENST00000277554, ENST00000467669, | ENST00000277120, ENST00000304053, ENST00000323115, ENST00000359847, ENST00000376208, ENST00000376213, ENST00000376214, ENST00000395866, ENST00000395882, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 4 X 4 X 4=64 | 10 X 9 X 7=630 |
# samples | 5 | 10 | |
** MAII score | log2(5/64*10)=-0.356143810225275 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(10/630*10)=-2.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context (manual curation of fusion genes in FusionPDB) | PubMed: NACC2 [Title/Abstract] AND NTRK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | |||
Anticipated loss of major functional domain due to fusion event. | NACC2-NTRK2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. NACC2-NTRK2 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF. NACC2-NTRK2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. NACC2-NTRK2 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | NACC2 | GO:0008285 | negative regulation of cell proliferation | 22926524 |
Hgene | NACC2 | GO:0034629 | cellular protein-containing complex localization | 22926524 |
Hgene | NACC2 | GO:0045892 | negative regulation of transcription, DNA-templated | 22926524 |
Hgene | NACC2 | GO:0051260 | protein homooligomerization | 22926524 |
Hgene | NACC2 | GO:1900477 | negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter | 22926524 |
Hgene | NACC2 | GO:1902231 | positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 22926524 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerKB3 | . | . | NACC2 | chr9 | 138905709 | - | NTRK2 | chr9 | 87359887 | + |
Top |
Fusion ORF Analysis |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000376214 | NTRK2 | chr9 | 87359887 | + | 4788 | 1313 | 1306 | 2634 | 442 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000376213 | NTRK2 | chr9 | 87359887 | + | 4740 | 1313 | 1306 | 2586 | 426 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000395882 | NTRK2 | chr9 | 87359887 | + | 6679 | 1313 | 123 | 1334 | 403 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000304053 | NTRK2 | chr9 | 87359887 | + | 7861 | 1313 | 123 | 1334 | 403 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000376208 | NTRK2 | chr9 | 87359887 | + | 7813 | 1313 | 123 | 1334 | 403 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000277120 | NTRK2 | chr9 | 87359887 | + | 3692 | 1313 | 1306 | 2634 | 442 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000323115 | NTRK2 | chr9 | 87359887 | + | 3473 | 1313 | 1306 | 2586 | 426 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000359847 | NTRK2 | chr9 | 87359887 | + | 6675 | 1313 | 123 | 1334 | 403 |
ENST00000277554 | NACC2 | chr9 | 138905709 | - | ENST00000395866 | NTRK2 | chr9 | 87359887 | + | 2036 | 1313 | 123 | 1334 | 403 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Amino Acid Sequences |
![]() |
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >57095_57095_1_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000277120_length(amino acids)=442AA_BP=2 MTDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKDFSWFGFGKVKSRQGVGPASV ISNDDDSASPLHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNL CPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQ SQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLG -------------------------------------------------------------- >57095_57095_2_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000304053_length(amino acids)=403AA_BP= MRAQPRRCPPAMSQMLHIEIPNFGNTVLGCLNEQRLLGLYCDVSIVVKGQAFKAHRAVLAASSLYFRDLFSGNSKSAFELPGSVPPACFQ QILSFCYTGRLTMTASEQLVVMYTAGFLQIQHIVERGTDLMFKVSSPHCDSQTAVIEDAGSEPQSPCNQLQPAAAAAAPYVVSPSVPIPL LTRVKHEAMELPPAGPGLAPKRPLETGPRDGVAVAAGAAVAAGTAPLKLPRVSYYGVPSLATLIPGIQQMPYPQGERTSPGASSLPTTDS PTSYHNEEDEEDDEAYDTMVEEQYGQMYIKASGSYAVQEKPEPVPLESRSCVLIRRDLVALPASLISQIGYRCHPKLYSEGDPGEKLELV -------------------------------------------------------------- >57095_57095_3_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000323115_length(amino acids)=426AA_BP=2 MTDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISN GSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKD ASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVY LASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEIFTYGKQPWYQ -------------------------------------------------------------- >57095_57095_4_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000359847_length(amino acids)=403AA_BP= MRAQPRRCPPAMSQMLHIEIPNFGNTVLGCLNEQRLLGLYCDVSIVVKGQAFKAHRAVLAASSLYFRDLFSGNSKSAFELPGSVPPACFQ QILSFCYTGRLTMTASEQLVVMYTAGFLQIQHIVERGTDLMFKVSSPHCDSQTAVIEDAGSEPQSPCNQLQPAAAAAAPYVVSPSVPIPL LTRVKHEAMELPPAGPGLAPKRPLETGPRDGVAVAAGAAVAAGTAPLKLPRVSYYGVPSLATLIPGIQQMPYPQGERTSPGASSLPTTDS PTSYHNEEDEEDDEAYDTMVEEQYGQMYIKASGSYAVQEKPEPVPLESRSCVLIRRDLVALPASLISQIGYRCHPKLYSEGDPGEKLELV -------------------------------------------------------------- >57095_57095_5_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000376208_length(amino acids)=403AA_BP= MRAQPRRCPPAMSQMLHIEIPNFGNTVLGCLNEQRLLGLYCDVSIVVKGQAFKAHRAVLAASSLYFRDLFSGNSKSAFELPGSVPPACFQ QILSFCYTGRLTMTASEQLVVMYTAGFLQIQHIVERGTDLMFKVSSPHCDSQTAVIEDAGSEPQSPCNQLQPAAAAAAPYVVSPSVPIPL LTRVKHEAMELPPAGPGLAPKRPLETGPRDGVAVAAGAAVAAGTAPLKLPRVSYYGVPSLATLIPGIQQMPYPQGERTSPGASSLPTTDS PTSYHNEEDEEDDEAYDTMVEEQYGQMYIKASGSYAVQEKPEPVPLESRSCVLIRRDLVALPASLISQIGYRCHPKLYSEGDPGEKLELV -------------------------------------------------------------- >57095_57095_6_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000376213_length(amino acids)=426AA_BP=2 MTDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISN GSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKD ASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVY LASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEIFTYGKQPWYQ -------------------------------------------------------------- >57095_57095_7_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000376214_length(amino acids)=442AA_BP=2 MTDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKDFSWFGFGKVKSRQGVGPASV ISNDDDSASPLHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNL CPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQ SQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLG -------------------------------------------------------------- >57095_57095_8_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000395866_length(amino acids)=403AA_BP= MRAQPRRCPPAMSQMLHIEIPNFGNTVLGCLNEQRLLGLYCDVSIVVKGQAFKAHRAVLAASSLYFRDLFSGNSKSAFELPGSVPPACFQ QILSFCYTGRLTMTASEQLVVMYTAGFLQIQHIVERGTDLMFKVSSPHCDSQTAVIEDAGSEPQSPCNQLQPAAAAAAPYVVSPSVPIPL LTRVKHEAMELPPAGPGLAPKRPLETGPRDGVAVAAGAAVAAGTAPLKLPRVSYYGVPSLATLIPGIQQMPYPQGERTSPGASSLPTTDS PTSYHNEEDEEDDEAYDTMVEEQYGQMYIKASGSYAVQEKPEPVPLESRSCVLIRRDLVALPASLISQIGYRCHPKLYSEGDPGEKLELV -------------------------------------------------------------- >57095_57095_9_NACC2-NTRK2_NACC2_chr9_138905709_ENST00000277554_NTRK2_chr9_87359887_ENST00000395882_length(amino acids)=403AA_BP= MRAQPRRCPPAMSQMLHIEIPNFGNTVLGCLNEQRLLGLYCDVSIVVKGQAFKAHRAVLAASSLYFRDLFSGNSKSAFELPGSVPPACFQ QILSFCYTGRLTMTASEQLVVMYTAGFLQIQHIVERGTDLMFKVSSPHCDSQTAVIEDAGSEPQSPCNQLQPAAAAAAPYVVSPSVPIPL LTRVKHEAMELPPAGPGLAPKRPLETGPRDGVAVAAGAAVAAGTAPLKLPRVSYYGVPSLATLIPGIQQMPYPQGERTSPGASSLPTTDS PTSYHNEEDEEDDEAYDTMVEEQYGQMYIKASGSYAVQEKPEPVPLESRSCVLIRRDLVALPASLISQIGYRCHPKLYSEGDPGEKLELV -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:/chr9:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
NACC2 | NTRK2 |
FUNCTION: Functions as a transcriptional repressor through its association with the NuRD complex. Recruits the NuRD complex to the promoter of MDM2, leading to the repression of MDM2 transcription and subsequent stability of p53/TP53. {ECO:0000269|PubMed:22926524}. | FUNCTION: Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:7574684, PubMed:15494731). Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:15494731). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia. {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, ECO:0000269|PubMed:7574684}. |
![]() |
- Retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- Not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Protein Structures |
![]() * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
PDB file (163) >>>163.pdbFusion protein BP residue: CIF file (163) >>>163.cif | NACC2 | chr9 | 138905709 | - | NTRK2 | chr9 | 87359887 | + | MRAQPRRCPPAMSQMLHIEIPNFGNTVLGCLNEQRLLGLYCDVSIVVKGQ AFKAHRAVLAASSLYFRDLFSGNSKSAFELPGSVPPACFQQILSFCYTGR LTMTASEQLVVMYTAGFLQIQHIVERGTDLMFKVSSPHCDSQTAVIEDAG SEPQSPCNQLQPAAAAAAPYVVSPSVPIPLLTRVKHEAMELPPAGPGLAP KRPLETGPRDGVAVAAGAAVAAGTAPLKLPRVSYYGVPSLATLIPGIQQM PYPQGERTSPGASSLPTTDSPTSYHNEEDEEDDEAYDTMVEEQYGQMYIK ASGSYAVQEKPEPVPLESRSCVLIRRDLVALPASLISQIGYRCHPKLYSE GDPGEKLELVAGSGVYITRGQLMNCHLCAGVKHKVLLRRLLATFFDRLWN | 403 |
3D view using mol* of 163 (AA BP:) | ||||||||||
![]() | ||||||||||
PDB file (186) >>>186.pdbFusion protein BP residue: 2 CIF file (186) >>>186.cif | NACC2 | chr9 | 138905709 | - | NTRK2 | chr9 | 87359887 | + | MTDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFC LLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISNGSNTPSSSEG GPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGE GAFGKVFLAECYNLCPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQ HEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPT ELTQSQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFG MSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEI FTYGKQPWYQLSNNEVIECITQGRVLQRPRTCPQEVYELMLGCWQREPHM | 426 |
3D view using mol* of 186 (AA BP:2) | ||||||||||
![]() | ||||||||||
PDB file (204) >>>204.pdbFusion protein BP residue: 2 CIF file (204) >>>204.cif | NACC2 | chr9 | 138905709 | - | NTRK2 | chr9 | 87359887 | + | MTDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFC LLVMLFLLKLARHSKFGMKDFSWFGFGKVKSRQGVGPASVISNDDDSASP LHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFV QHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKDASDN ARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLR AHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVYLASQHFVHRDLATR NCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKF TTESDVWSLGVVLWEIFTYGKQPWYQLSNNEVIECITQGRVLQRPRTCPQ | 442 |
3D view using mol* of 204 (AA BP:2) | ||||||||||
![]() |
Top |
pLDDT score distribution |
![]() * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
NACC2_pLDDT.png![]() |
NTRK2_pLDDT.png![]() |
![]() * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
Top |
Ramachandran Plot of Fusion Protein Structure |
![]() |
Fusion AA seq ID in FusionPDB and their Ramachandran plots |
NACC2_NTRK2_163.png |
![]() |
NACC2_NTRK2_186.png |
![]() |
NACC2_NTRK2_204.png |
![]() |
Top |
Potential Active Site Information |
![]() |
Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
163 | 1.076 | 232 | 1.125 | 606.767 | 0.413 | 0.742 | 1.005 | 1.438 | 0.799 | 1.8 | 1.069 | Chain A: 64,65,83,84,109,112,113,114,116,117,119,1 21,124,125,128,129,131,132,369,372,373,376,377,379 ,380,381,384,385,388,389,391,392,394,395,396 |
186 | 1.047 | 140 | 0.995 | 530.278 | 0.568 | 0.768 | 0.995 | 0.347 | 1.246 | 0.278 | 0.888 | Chain A: 73,74,75,79,80,81,83,84,85,86,88,89,151,1 52,153,176,178,179,180,182,184,185,188,189,192,219 ,298,299,300,303,304,307,310,312,318 |
204 | 1.053 | 372 | 1.1 | 1044.092 | 0.536 | 0.715 | 0.936 | 0.992 | 0.823 | 1.206 | 1.035 | Chain A: 115,116,117,118,119,120,121,122,127,130,1 32,133,134,135,136,137,139,140,143,144,145,167,168 ,169,192,193,194,196,201,204,205,207,208,211,212,2 14,215,235,286,289,290,291,292,293,294,295,296,301 ,314,315,316,317,318,320,323,326,329,330,332,333,3 34,335,336,340,348,350,358 |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
![]() |
Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
![]() |
ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
![]() |
ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
![]() |
ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
![]() |
![]() |
Gene | PPI interactors |
NACC2 | EPS8, NACC2, HDAC1, HDAC2, MTA1, MTA2, RBBP7, RBBP4, CHD4, MTA3, FOXP3, TRIM25, HNRNPL, TP63, NACC1, BCAN, ZBTB34, OSBPL1A, FHL2, GOPC, FEM1A, TRAPPC9, B4GALT2, DNAJB6, TWIST2, RPP21, SENP3, DHDH, SOHLH1, KLHDC10, HSPB8, C11orf71, PPARD, RFXANK, CPNE4, TPGS1, NPAS1, DCTN3, ZYG11B, KLHL22, TFPT, DNAJB8, CIB3, C6orf141, MEF2BNB, NCAPH2, INF2, AANAT, |
![]() |
Gene | STRING network |
NACC2 | ![]() |
NTRK2 | ![]() |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to NACC2-NTRK2 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to NACC2-NTRK2 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
NACC2 | NTRK2 | Squamous Cell Carcinoma | MyCancerGenome | |
NACC2 | NTRK2 | Cancer Of Unknown Primary | MyCancerGenome | |
NACC2 | NTRK2 | Nos | MyCancerGenome | |
NACC2 | NTRK2 | High-Grade Neuroepithelial Tumor | MyCancerGenome | |
NACC2 | NTRK2 | Invasive Breast Carcinoma | MyCancerGenome | |
NACC2 | NTRK2 | Lung Adenocarcinoma | MyCancerGenome |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | NTRK2 | C0011570 | Mental Depression | 5 | PSYGENET |
Tgene | NTRK2 | C0011581 | Depressive disorder | 5 | PSYGENET |
Tgene | NTRK2 | C0041696 | Unipolar Depression | 5 | PSYGENET |
Tgene | NTRK2 | C0525045 | Mood Disorders | 5 | PSYGENET |
Tgene | NTRK2 | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
Tgene | NTRK2 | C3151303 | Obesity, Hyperphagia, and Developmental Delay | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | NTRK2 | C0005586 | Bipolar Disorder | 3 | CTD_human;PSYGENET |
Tgene | NTRK2 | C4693367 | EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 58 | 3 | GENOMICS_ENGLAND;UNIPROT |
Tgene | NTRK2 | C0009171 | Cocaine Abuse | 2 | CTD_human |
Tgene | NTRK2 | C0036341 | Schizophrenia | 2 | PSYGENET |
Tgene | NTRK2 | C0038220 | Status Epilepticus | 2 | CTD_human |
Tgene | NTRK2 | C0236736 | Cocaine-Related Disorders | 2 | CTD_human |
Tgene | NTRK2 | C0270823 | Petit mal status | 2 | CTD_human |
Tgene | NTRK2 | C0311335 | Grand Mal Status Epilepticus | 2 | CTD_human |
Tgene | NTRK2 | C0393734 | Complex Partial Status Epilepticus | 2 | CTD_human |
Tgene | NTRK2 | C0600427 | Cocaine Dependence | 2 | CTD_human |
Tgene | NTRK2 | C0751217 | Hyperkinesia, Generalized | 2 | CTD_human |
Tgene | NTRK2 | C0751522 | Status Epilepticus, Subclinical | 2 | CTD_human |
Tgene | NTRK2 | C0751523 | Non-Convulsive Status Epilepticus | 2 | CTD_human |
Tgene | NTRK2 | C0751524 | Simple Partial Status Epilepticus | 2 | CTD_human |
Tgene | NTRK2 | C3887506 | Hyperkinesia | 2 | CTD_human |
Tgene | NTRK2 | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
Tgene | NTRK2 | C0004114 | Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0004352 | Autistic Disorder | 1 | CTD_human |
Tgene | NTRK2 | C0005587 | Depression, Bipolar | 1 | CTD_human |
Tgene | NTRK2 | C0008073 | Developmental Disabilities | 1 | CTD_human |
Tgene | NTRK2 | C0013415 | Dysthymic Disorder | 1 | PSYGENET |
Tgene | NTRK2 | C0017638 | Glioma | 1 | CTD_human |
Tgene | NTRK2 | C0020505 | Hyperphagia | 1 | CTD_human |
Tgene | NTRK2 | C0024713 | Manic Disorder | 1 | CTD_human |
Tgene | NTRK2 | C0027819 | Neuroblastoma | 1 | CTD_human |
Tgene | NTRK2 | C0028754 | Obesity | 1 | CTD_human |
Tgene | NTRK2 | C0036349 | Paranoid Schizophrenia | 1 | PSYGENET |
Tgene | NTRK2 | C0037769 | West Syndrome | 1 | ORPHANET |
Tgene | NTRK2 | C0085996 | Child Development Deviations | 1 | CTD_human |
Tgene | NTRK2 | C0085997 | Child Development Disorders, Specific | 1 | CTD_human |
Tgene | NTRK2 | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0259783 | mixed gliomas | 1 | CTD_human |
Tgene | NTRK2 | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0334579 | Anaplastic astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0334583 | Pilocytic Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0338831 | Manic | 1 | CTD_human |
Tgene | NTRK2 | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0555198 | Malignant Glioma | 1 | CTD_human |
Tgene | NTRK2 | C0678807 | prenatal alcohol exposure | 1 | PSYGENET |
Tgene | NTRK2 | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C0752347 | Lewy Body Disease | 1 | CTD_human |
Tgene | NTRK2 | C1519086 | Pilomyxoid astrocytoma | 1 | ORPHANET |
Tgene | NTRK2 | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
Tgene | NTRK2 | C3146244 | Alcohol Related Birth Defect | 1 | PSYGENET |